nodes	percent_of_prediction	percent_of_DWPC	metapath
Agomelatine—CYP1A2—Imiquimod—skin cancer	0.228	0.327	CbGbCtD
Agomelatine—CYP2C9—Vismodegib—skin cancer	0.142	0.204	CbGbCtD
Agomelatine—CYP1A2—Vemurafenib—skin cancer	0.125	0.179	CbGbCtD
Agomelatine—CYP1A2—Dacarbazine—skin cancer	0.0955	0.137	CbGbCtD
Agomelatine—CYP1A2—Fluorouracil—skin cancer	0.056	0.0804	CbGbCtD
Agomelatine—CYP2C9—Fluorouracil—skin cancer	0.0505	0.0725	CbGbCtD
Agomelatine—MTNR1A—Small Ligand GPCRs—PTGER4—skin cancer	0.00715	0.108	CbGpPWpGaD
Agomelatine—MTNR1B—Small Ligand GPCRs—PTGER4—skin cancer	0.00715	0.108	CbGpPWpGaD
Agomelatine—Phosphatase alkaline increased—Vismodegib—skin cancer	0.00668	0.0286	CcSEcCtD
Agomelatine—Blood alkaline phosphatase increased—Vismodegib—skin cancer	0.00558	0.0239	CcSEcCtD
Agomelatine—Rash erythematous—Imiquimod—skin cancer	0.0046	0.0197	CcSEcCtD
Agomelatine—Weight decreased—Vismodegib—skin cancer	0.00379	0.0162	CcSEcCtD
Agomelatine—Connective tissue disorder—Vismodegib—skin cancer	0.0033	0.0141	CcSEcCtD
Agomelatine—Aggression—Bleomycin—skin cancer	0.00285	0.0122	CcSEcCtD
Agomelatine—Eczema—Imiquimod—skin cancer	0.00284	0.0122	CcSEcCtD
Agomelatine—Back pain—Vismodegib—skin cancer	0.00282	0.0121	CcSEcCtD
Agomelatine—Migraine—Imiquimod—skin cancer	0.00251	0.0108	CcSEcCtD
Agomelatine—Unspecified disorder of skin and subcutaneous tissue—Vismodegib—skin cancer	0.00247	0.0106	CcSEcCtD
Agomelatine—Face oedema—Imiquimod—skin cancer	0.00247	0.0106	CcSEcCtD
Agomelatine—Irritability—Imiquimod—skin cancer	0.00244	0.0104	CcSEcCtD
Agomelatine—Weight decreased—Vemurafenib—skin cancer	0.00234	0.01	CcSEcCtD
Agomelatine—Nervous system disorder—Vismodegib—skin cancer	0.00234	0.01	CcSEcCtD
Agomelatine—Skin disorder—Vismodegib—skin cancer	0.00232	0.00992	CcSEcCtD
Agomelatine—Infestation NOS—Vemurafenib—skin cancer	0.00231	0.00989	CcSEcCtD
Agomelatine—Infestation—Vemurafenib—skin cancer	0.00231	0.00989	CcSEcCtD
Agomelatine—Nabumetone—PTGS2—skin cancer	0.00227	0.544	CrCbGaD
Agomelatine—Influenza—Imiquimod—skin cancer	0.00221	0.00946	CcSEcCtD
Agomelatine—Phosphatase alkaline increased—Temozolomide—skin cancer	0.00211	0.00904	CcSEcCtD
Agomelatine—Dyspepsia—Vismodegib—skin cancer	0.0021	0.00899	CcSEcCtD
Agomelatine—Gastrointestinal disorder—Vismodegib—skin cancer	0.00206	0.00881	CcSEcCtD
Agomelatine—Fatigue—Vismodegib—skin cancer	0.00205	0.0088	CcSEcCtD
Agomelatine—Constipation—Vismodegib—skin cancer	0.00204	0.00873	CcSEcCtD
Agomelatine—Connective tissue disorder—Vemurafenib—skin cancer	0.00204	0.00872	CcSEcCtD
Agomelatine—MTNR1A—Circadian rythm related genes—NKX2-1—skin cancer	0.00203	0.0308	CbGpPWpGaD
Agomelatine—MTNR1B—Circadian rythm related genes—NKX2-1—skin cancer	0.00203	0.0308	CbGpPWpGaD
Agomelatine—Infestation NOS—Imiquimod—skin cancer	0.00197	0.00843	CcSEcCtD
Agomelatine—Infestation—Imiquimod—skin cancer	0.00197	0.00843	CcSEcCtD
Agomelatine—Depression—Imiquimod—skin cancer	0.00196	0.00841	CcSEcCtD
Agomelatine—Gastrointestinal pain—Vismodegib—skin cancer	0.00195	0.00835	CcSEcCtD
Agomelatine—Eye disorder—Vemurafenib—skin cancer	0.00194	0.0083	CcSEcCtD
Agomelatine—Abdominal pain—Vismodegib—skin cancer	0.00188	0.00807	CcSEcCtD
Agomelatine—Hepatic failure—Dactinomycin—skin cancer	0.00188	0.00807	CcSEcCtD
Agomelatine—Hepatobiliary disease—Imiquimod—skin cancer	0.00186	0.00798	CcSEcCtD
Agomelatine—Rash erythematous—Docetaxel—skin cancer	0.00183	0.00785	CcSEcCtD
Agomelatine—Blood alkaline phosphatase increased—Temozolomide—skin cancer	0.00176	0.00754	CcSEcCtD
Agomelatine—Back pain—Vemurafenib—skin cancer	0.00175	0.00748	CcSEcCtD
Agomelatine—Connective tissue disorder—Imiquimod—skin cancer	0.00174	0.00744	CcSEcCtD
Agomelatine—Asthenia—Vismodegib—skin cancer	0.00171	0.00733	CcSEcCtD
Agomelatine—Hepatic failure—Temozolomide—skin cancer	0.0017	0.0073	CcSEcCtD
Agomelatine—Pruritus—Vismodegib—skin cancer	0.00169	0.00722	CcSEcCtD
Agomelatine—Eye disorder—Imiquimod—skin cancer	0.00165	0.00708	CcSEcCtD
Agomelatine—Tinnitus—Imiquimod—skin cancer	0.00165	0.00706	CcSEcCtD
Agomelatine—Diarrhoea—Vismodegib—skin cancer	0.00163	0.00699	CcSEcCtD
Agomelatine—Mental disorder—Imiquimod—skin cancer	0.00155	0.00663	CcSEcCtD
Agomelatine—Unspecified disorder of skin and subcutaneous tissue—Vemurafenib—skin cancer	0.00153	0.00653	CcSEcCtD
Agomelatine—Vomiting—Vismodegib—skin cancer	0.00152	0.00649	CcSEcCtD
Agomelatine—Back pain—Imiquimod—skin cancer	0.00149	0.00638	CcSEcCtD
Agomelatine—Face oedema—Temozolomide—skin cancer	0.00148	0.00633	CcSEcCtD
Agomelatine—Infection—Vemurafenib—skin cancer	0.00146	0.00627	CcSEcCtD
Agomelatine—Nervous system disorder—Vemurafenib—skin cancer	0.00144	0.00619	CcSEcCtD
Agomelatine—Skin disorder—Vemurafenib—skin cancer	0.00143	0.00613	CcSEcCtD
Agomelatine—Weight decreased—Bleomycin—skin cancer	0.00142	0.00608	CcSEcCtD
Agomelatine—Nausea—Vismodegib—skin cancer	0.00142	0.00606	CcSEcCtD
Agomelatine—Agitation—Imiquimod—skin cancer	0.00141	0.00606	CcSEcCtD
Agomelatine—Angioedema—Imiquimod—skin cancer	0.00141	0.00602	CcSEcCtD
Agomelatine—Phosphatase alkaline increased—Docetaxel—skin cancer	0.0014	0.00601	CcSEcCtD
Agomelatine—MTNR1A—GPCRs, Class A Rhodopsin-like—MC1R—skin cancer	0.00135	0.0204	CbGpPWpGaD
Agomelatine—MTNR1B—GPCRs, Class A Rhodopsin-like—MC1R—skin cancer	0.00135	0.0204	CbGpPWpGaD
Agomelatine—Irritability—Fluorouracil—skin cancer	0.00135	0.00577	CcSEcCtD
Agomelatine—Anxiety—Imiquimod—skin cancer	0.00131	0.00559	CcSEcCtD
Agomelatine—Unspecified disorder of skin and subcutaneous tissue—Imiquimod—skin cancer	0.0013	0.00557	CcSEcCtD
Agomelatine—Dry mouth—Imiquimod—skin cancer	0.00128	0.00549	CcSEcCtD
Agomelatine—Gastrointestinal disorder—Vemurafenib—skin cancer	0.00127	0.00545	CcSEcCtD
Agomelatine—Fatigue—Vemurafenib—skin cancer	0.00127	0.00544	CcSEcCtD
Agomelatine—Nasopharyngitis—Fluorouracil—skin cancer	0.00126	0.0054	CcSEcCtD
Agomelatine—Constipation—Vemurafenib—skin cancer	0.00126	0.00539	CcSEcCtD
Agomelatine—Infection—Imiquimod—skin cancer	0.00125	0.00534	CcSEcCtD
Agomelatine—Nervous system disorder—Imiquimod—skin cancer	0.00123	0.00528	CcSEcCtD
Agomelatine—Skin disorder—Imiquimod—skin cancer	0.00122	0.00522	CcSEcCtD
Agomelatine—MTNR1B—GPCR ligand binding—PTCH2—skin cancer	0.00122	0.0185	CbGpPWpGaD
Agomelatine—MTNR1A—GPCR ligand binding—PTCH2—skin cancer	0.00122	0.0185	CbGpPWpGaD
Agomelatine—Hyperhidrosis—Imiquimod—skin cancer	0.00121	0.0052	CcSEcCtD
Agomelatine—Weight increased—Temozolomide—skin cancer	0.0012	0.00516	CcSEcCtD
Agomelatine—Weight decreased—Temozolomide—skin cancer	0.0012	0.00513	CcSEcCtD
Agomelatine—Infestation NOS—Temozolomide—skin cancer	0.00118	0.00505	CcSEcCtD
Agomelatine—Infestation—Temozolomide—skin cancer	0.00118	0.00505	CcSEcCtD
Agomelatine—Depression—Temozolomide—skin cancer	0.00118	0.00504	CcSEcCtD
Agomelatine—Hepatitis—Dactinomycin—skin cancer	0.00117	0.00502	CcSEcCtD
Agomelatine—Blood alkaline phosphatase increased—Docetaxel—skin cancer	0.00117	0.00501	CcSEcCtD
Agomelatine—MTNR1B—Class A/1 (Rhodopsin-like receptors)—MC1R—skin cancer	0.00116	0.0175	CbGpPWpGaD
Agomelatine—MTNR1A—Class A/1 (Rhodopsin-like receptors)—MC1R—skin cancer	0.00116	0.0175	CbGpPWpGaD
Agomelatine—Insomnia—Imiquimod—skin cancer	0.00114	0.00487	CcSEcCtD
Agomelatine—Hepatic failure—Docetaxel—skin cancer	0.00113	0.00485	CcSEcCtD
Agomelatine—Paraesthesia—Imiquimod—skin cancer	0.00113	0.00483	CcSEcCtD
Agomelatine—Somnolence—Imiquimod—skin cancer	0.00112	0.00478	CcSEcCtD
Agomelatine—Hepatobiliary disease—Temozolomide—skin cancer	0.00112	0.00478	CcSEcCtD
Agomelatine—Dyspepsia—Imiquimod—skin cancer	0.00111	0.00474	CcSEcCtD
Agomelatine—Infestation NOS—Fluorouracil—skin cancer	0.00109	0.00466	CcSEcCtD
Agomelatine—Infestation—Fluorouracil—skin cancer	0.00109	0.00466	CcSEcCtD
Agomelatine—Gastrointestinal disorder—Imiquimod—skin cancer	0.00108	0.00464	CcSEcCtD
Agomelatine—Fatigue—Imiquimod—skin cancer	0.00108	0.00464	CcSEcCtD
Agomelatine—Hepatitis—Temozolomide—skin cancer	0.00106	0.00454	CcSEcCtD
Agomelatine—Asthenia—Vemurafenib—skin cancer	0.00106	0.00453	CcSEcCtD
Agomelatine—Hallucination—Temozolomide—skin cancer	0.00105	0.00451	CcSEcCtD
Agomelatine—Naproxen—PTGS2—skin cancer	0.00105	0.252	CrCbGaD
Agomelatine—Pruritus—Vemurafenib—skin cancer	0.00104	0.00446	CcSEcCtD
Agomelatine—Connective tissue disorder—Temozolomide—skin cancer	0.00104	0.00446	CcSEcCtD
Agomelatine—Gastrointestinal pain—Imiquimod—skin cancer	0.00103	0.0044	CcSEcCtD
Agomelatine—Diarrhoea—Vemurafenib—skin cancer	0.00101	0.00432	CcSEcCtD
Agomelatine—Migraine—Docetaxel—skin cancer	0.001	0.00429	CcSEcCtD
Agomelatine—Urticaria—Imiquimod—skin cancer	0.000998	0.00427	CcSEcCtD
Agomelatine—Abdominal pain—Imiquimod—skin cancer	0.000993	0.00425	CcSEcCtD
Agomelatine—Eye disorder—Temozolomide—skin cancer	0.00099	0.00424	CcSEcCtD
Agomelatine—Tinnitus—Temozolomide—skin cancer	0.000988	0.00423	CcSEcCtD
Agomelatine—Dizziness—Vemurafenib—skin cancer	0.000974	0.00417	CcSEcCtD
Agomelatine—Vomiting—Vemurafenib—skin cancer	0.000936	0.00401	CcSEcCtD
Agomelatine—Mental disorder—Temozolomide—skin cancer	0.000928	0.00398	CcSEcCtD
Agomelatine—Headache—Vemurafenib—skin cancer	0.000922	0.00395	CcSEcCtD
Agomelatine—Nasopharyngitis—Docetaxel—skin cancer	0.000911	0.0039	CcSEcCtD
Agomelatine—Asthenia—Imiquimod—skin cancer	0.000901	0.00386	CcSEcCtD
Agomelatine—Back pain—Temozolomide—skin cancer	0.000892	0.00382	CcSEcCtD
Agomelatine—Pruritus—Imiquimod—skin cancer	0.000888	0.00381	CcSEcCtD
Agomelatine—MTNR1B—GPCRs, Class A Rhodopsin-like—PTGER4—skin cancer	0.000888	0.0134	CbGpPWpGaD
Agomelatine—MTNR1A—GPCRs, Class A Rhodopsin-like—PTGER4—skin cancer	0.000888	0.0134	CbGpPWpGaD
Agomelatine—Infection—Bleomycin—skin cancer	0.000886	0.0038	CcSEcCtD
Agomelatine—MTNR1A—GPCR ligand binding—MC1R—skin cancer	0.000881	0.0133	CbGpPWpGaD
Agomelatine—MTNR1B—GPCR ligand binding—MC1R—skin cancer	0.000881	0.0133	CbGpPWpGaD
Agomelatine—Nausea—Vemurafenib—skin cancer	0.000875	0.00375	CcSEcCtD
Agomelatine—Vision blurred—Temozolomide—skin cancer	0.000869	0.00372	CcSEcCtD
Agomelatine—Tremor—Temozolomide—skin cancer	0.000864	0.0037	CcSEcCtD
Agomelatine—Diarrhoea—Imiquimod—skin cancer	0.000859	0.00368	CcSEcCtD
Agomelatine—Indomethacin—PTGS2—skin cancer	0.000849	0.204	CrCbGaD
Agomelatine—Agitation—Temozolomide—skin cancer	0.000847	0.00363	CcSEcCtD
Agomelatine—Angioedema—Temozolomide—skin cancer	0.000843	0.00361	CcSEcCtD
Agomelatine—Dizziness—Imiquimod—skin cancer	0.00083	0.00356	CcSEcCtD
Agomelatine—Vertigo—Temozolomide—skin cancer	0.000828	0.00355	CcSEcCtD
Agomelatine—Infection—Dactinomycin—skin cancer	0.000827	0.00354	CcSEcCtD
Agomelatine—Paraesthesia—Bleomycin—skin cancer	0.000801	0.00343	CcSEcCtD
Agomelatine—Weight increased—Docetaxel—skin cancer	0.000801	0.00343	CcSEcCtD
Agomelatine—Vision blurred—Fluorouracil—skin cancer	0.000801	0.00343	CcSEcCtD
Agomelatine—Vomiting—Imiquimod—skin cancer	0.000798	0.00342	CcSEcCtD
Agomelatine—Weight decreased—Docetaxel—skin cancer	0.000796	0.00341	CcSEcCtD
Agomelatine—Headache—Imiquimod—skin cancer	0.000787	0.00337	CcSEcCtD
Agomelatine—Infestation—Docetaxel—skin cancer	0.000785	0.00336	CcSEcCtD
Agomelatine—Infestation NOS—Docetaxel—skin cancer	0.000785	0.00336	CcSEcCtD
Agomelatine—Anxiety—Temozolomide—skin cancer	0.000782	0.00335	CcSEcCtD
Agomelatine—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	0.00078	0.00334	CcSEcCtD
Agomelatine—Dry mouth—Temozolomide—skin cancer	0.000768	0.00329	CcSEcCtD
Agomelatine—Jaundice—Docetaxel—skin cancer	0.000765	0.00328	CcSEcCtD
Agomelatine—MTNR1A—Class A/1 (Rhodopsin-like receptors)—PTGER4—skin cancer	0.000761	0.0115	CbGpPWpGaD
Agomelatine—MTNR1B—Class A/1 (Rhodopsin-like receptors)—PTGER4—skin cancer	0.000761	0.0115	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—RHOU—skin cancer	0.000756	0.0115	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—RHOU—skin cancer	0.000756	0.0115	CbGpPWpGaD
Agomelatine—Infection—Temozolomide—skin cancer	0.000748	0.0032	CcSEcCtD
Agomelatine—Nausea—Imiquimod—skin cancer	0.000746	0.0032	CcSEcCtD
Agomelatine—Hepatobiliary disease—Docetaxel—skin cancer	0.000742	0.00318	CcSEcCtD
Agomelatine—Nervous system disorder—Temozolomide—skin cancer	0.000738	0.00316	CcSEcCtD
Agomelatine—Skin disorder—Temozolomide—skin cancer	0.000731	0.00313	CcSEcCtD
Agomelatine—Hyperhidrosis—Temozolomide—skin cancer	0.000728	0.00312	CcSEcCtD
Agomelatine—Fatigue—Dactinomycin—skin cancer	0.000717	0.00307	CcSEcCtD
Agomelatine—Urticaria—Bleomycin—skin cancer	0.000709	0.00304	CcSEcCtD
Agomelatine—Hepatitis—Docetaxel—skin cancer	0.000704	0.00302	CcSEcCtD
Agomelatine—Connective tissue disorder—Docetaxel—skin cancer	0.000692	0.00297	CcSEcCtD
Agomelatine—Infection—Fluorouracil—skin cancer	0.000689	0.00295	CcSEcCtD
Agomelatine—Insomnia—Temozolomide—skin cancer	0.000681	0.00292	CcSEcCtD
Agomelatine—Gastrointestinal pain—Dactinomycin—skin cancer	0.00068	0.00291	CcSEcCtD
Agomelatine—Nervous system disorder—Fluorouracil—skin cancer	0.00068	0.00291	CcSEcCtD
Agomelatine—Paraesthesia—Temozolomide—skin cancer	0.000676	0.00289	CcSEcCtD
Agomelatine—Somnolence—Temozolomide—skin cancer	0.000669	0.00287	CcSEcCtD
Agomelatine—Dyspepsia—Temozolomide—skin cancer	0.000662	0.00284	CcSEcCtD
Agomelatine—Eye disorder—Docetaxel—skin cancer	0.000658	0.00282	CcSEcCtD
Agomelatine—Abdominal pain—Dactinomycin—skin cancer	0.000658	0.00282	CcSEcCtD
Agomelatine—HTR2B—Serotonin Receptor 2 and ELK-SRF/GATA4 signaling—NRAS—skin cancer	0.000651	0.00986	CbGpPWpGaD
Agomelatine—Gastrointestinal disorder—Temozolomide—skin cancer	0.00065	0.00278	CcSEcCtD
Agomelatine—Fatigue—Temozolomide—skin cancer	0.000649	0.00278	CcSEcCtD
Agomelatine—Constipation—Temozolomide—skin cancer	0.000644	0.00276	CcSEcCtD
Agomelatine—Asthenia—Bleomycin—skin cancer	0.00064	0.00274	CcSEcCtD
Agomelatine—Pruritus—Bleomycin—skin cancer	0.000631	0.0027	CcSEcCtD
Agomelatine—MTNR1A—GPCR ligand binding—SHH—skin cancer	0.000628	0.00951	CbGpPWpGaD
Agomelatine—MTNR1B—GPCR ligand binding—SHH—skin cancer	0.000628	0.00951	CbGpPWpGaD
Agomelatine—Insomnia—Fluorouracil—skin cancer	0.000627	0.00269	CcSEcCtD
Agomelatine—MTNR1A—Signaling by GPCR—PTCH2—skin cancer	0.000625	0.00947	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling by GPCR—PTCH2—skin cancer	0.000625	0.00947	CbGpPWpGaD
Agomelatine—Paraesthesia—Fluorouracil—skin cancer	0.000623	0.00267	CcSEcCtD
Agomelatine—Mental disorder—Docetaxel—skin cancer	0.000617	0.00264	CcSEcCtD
Agomelatine—Somnolence—Fluorouracil—skin cancer	0.000616	0.00264	CcSEcCtD
Agomelatine—Gastrointestinal pain—Temozolomide—skin cancer	0.000615	0.00264	CcSEcCtD
Agomelatine—Dyspepsia—Fluorouracil—skin cancer	0.00061	0.00261	CcSEcCtD
Agomelatine—Gastrointestinal disorder—Fluorouracil—skin cancer	0.000599	0.00256	CcSEcCtD
Agomelatine—Urticaria—Temozolomide—skin cancer	0.000598	0.00256	CcSEcCtD
Agomelatine—Asthenia—Dactinomycin—skin cancer	0.000597	0.00256	CcSEcCtD
Agomelatine—MTNR1A—GPCR ligand binding—SMO—skin cancer	0.000595	0.00901	CbGpPWpGaD
Agomelatine—MTNR1A—GPCR ligand binding—PTCH1—skin cancer	0.000595	0.00901	CbGpPWpGaD
Agomelatine—MTNR1B—GPCR ligand binding—SMO—skin cancer	0.000595	0.00901	CbGpPWpGaD
Agomelatine—MTNR1B—GPCR ligand binding—PTCH1—skin cancer	0.000595	0.00901	CbGpPWpGaD
Agomelatine—Abdominal pain—Temozolomide—skin cancer	0.000595	0.00255	CcSEcCtD
Agomelatine—Back pain—Docetaxel—skin cancer	0.000593	0.00254	CcSEcCtD
Agomelatine—MTNR1B—GPCR ligand binding—PTGER4—skin cancer	0.000579	0.00877	CbGpPWpGaD
Agomelatine—MTNR1A—GPCR ligand binding—PTGER4—skin cancer	0.000579	0.00877	CbGpPWpGaD
Agomelatine—MTNR1A—Circadian rythm related genes—CDK4—skin cancer	0.000572	0.00867	CbGpPWpGaD
Agomelatine—MTNR1B—Circadian rythm related genes—CDK4—skin cancer	0.000572	0.00867	CbGpPWpGaD
Agomelatine—Diarrhoea—Dactinomycin—skin cancer	0.000569	0.00244	CcSEcCtD
Agomelatine—Vomiting—Bleomycin—skin cancer	0.000567	0.00243	CcSEcCtD
Agomelatine—HTR2B—Serotonin Receptor 2 and ELK-SRF/GATA4 signaling—KRAS—skin cancer	0.00056	0.00848	CbGpPWpGaD
Agomelatine—Urticaria—Fluorouracil—skin cancer	0.000551	0.00236	CcSEcCtD
Agomelatine—Asthenia—Temozolomide—skin cancer	0.00054	0.00231	CcSEcCtD
Agomelatine—Pruritus—Temozolomide—skin cancer	0.000532	0.00228	CcSEcCtD
Agomelatine—Nausea—Bleomycin—skin cancer	0.00053	0.00227	CcSEcCtD
Agomelatine—Vomiting—Dactinomycin—skin cancer	0.000529	0.00227	CcSEcCtD
Agomelatine—HTR2C—Serotonin Receptor 2 and ELK-SRF/GATA4 signaling—NRAS—skin cancer	0.000525	0.00795	CbGpPWpGaD
Agomelatine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	0.000518	0.00222	CcSEcCtD
Agomelatine—Diarrhoea—Temozolomide—skin cancer	0.000515	0.00221	CcSEcCtD
Agomelatine—Dry mouth—Docetaxel—skin cancer	0.000511	0.00219	CcSEcCtD
Agomelatine—MTNR1B—GPCR downstream signaling—MC1R—skin cancer	0.000498	0.00754	CbGpPWpGaD
Agomelatine—MTNR1A—GPCR downstream signaling—MC1R—skin cancer	0.000498	0.00754	CbGpPWpGaD
Agomelatine—Dizziness—Temozolomide—skin cancer	0.000498	0.00213	CcSEcCtD
Agomelatine—Infection—Docetaxel—skin cancer	0.000497	0.00213	CcSEcCtD
Agomelatine—Nausea—Dactinomycin—skin cancer	0.000494	0.00212	CcSEcCtD
Agomelatine—Nervous system disorder—Docetaxel—skin cancer	0.000491	0.0021	CcSEcCtD
Agomelatine—Pruritus—Fluorouracil—skin cancer	0.000491	0.0021	CcSEcCtD
Agomelatine—Skin disorder—Docetaxel—skin cancer	0.000486	0.00208	CcSEcCtD
Agomelatine—Vomiting—Temozolomide—skin cancer	0.000478	0.00205	CcSEcCtD
Agomelatine—HTR2B—Serotonin Receptor 2 and ELK-SRF/GATA4 signaling—HRAS—skin cancer	0.000476	0.00721	CbGpPWpGaD
Agomelatine—Diarrhoea—Fluorouracil—skin cancer	0.000474	0.00203	CcSEcCtD
Agomelatine—Headache—Temozolomide—skin cancer	0.000471	0.00202	CcSEcCtD
Agomelatine—Dizziness—Fluorouracil—skin cancer	0.000459	0.00196	CcSEcCtD
Agomelatine—Insomnia—Docetaxel—skin cancer	0.000453	0.00194	CcSEcCtD
Agomelatine—MTNR1B—Signaling by GPCR—MC1R—skin cancer	0.000452	0.00685	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling by GPCR—MC1R—skin cancer	0.000452	0.00685	CbGpPWpGaD
Agomelatine—HTR2C—Serotonin Receptor 2 and ELK-SRF/GATA4 signaling—KRAS—skin cancer	0.000452	0.00685	CbGpPWpGaD
Agomelatine—Paraesthesia—Docetaxel—skin cancer	0.000449	0.00192	CcSEcCtD
Agomelatine—Nausea—Temozolomide—skin cancer	0.000447	0.00191	CcSEcCtD
Agomelatine—Somnolence—Docetaxel—skin cancer	0.000445	0.00191	CcSEcCtD
Agomelatine—Vomiting—Fluorouracil—skin cancer	0.000441	0.00189	CcSEcCtD
Agomelatine—Dyspepsia—Docetaxel—skin cancer	0.000441	0.00189	CcSEcCtD
Agomelatine—HTR2B—GPCRs, Class A Rhodopsin-like—MC1R—skin cancer	0.000436	0.0066	CbGpPWpGaD
Agomelatine—Headache—Fluorouracil—skin cancer	0.000434	0.00186	CcSEcCtD
Agomelatine—Gastrointestinal disorder—Docetaxel—skin cancer	0.000432	0.00185	CcSEcCtD
Agomelatine—Fatigue—Docetaxel—skin cancer	0.000431	0.00185	CcSEcCtD
Agomelatine—Constipation—Docetaxel—skin cancer	0.000428	0.00183	CcSEcCtD
Agomelatine—Nausea—Fluorouracil—skin cancer	0.000412	0.00176	CcSEcCtD
Agomelatine—Gastrointestinal pain—Docetaxel—skin cancer	0.000409	0.00175	CcSEcCtD
Agomelatine—Abdominal pain—Docetaxel—skin cancer	0.000396	0.00169	CcSEcCtD
Agomelatine—HTR2B—GPCR ligand binding—PTCH2—skin cancer	0.000393	0.00596	CbGpPWpGaD
Agomelatine—HTR2C—Serotonin Receptor 2 and ELK-SRF/GATA4 signaling—HRAS—skin cancer	0.000384	0.00582	CbGpPWpGaD
Agomelatine—HTR2B—Class A/1 (Rhodopsin-like receptors)—MC1R—skin cancer	0.000373	0.00565	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—PTCH2—skin cancer	0.000369	0.00559	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—PTCH2—skin cancer	0.000369	0.00559	CbGpPWpGaD
Agomelatine—Asthenia—Docetaxel—skin cancer	0.000359	0.00154	CcSEcCtD
Agomelatine—Pruritus—Docetaxel—skin cancer	0.000354	0.00152	CcSEcCtD
Agomelatine—HTR2C—GPCRs, Class A Rhodopsin-like—MC1R—skin cancer	0.000352	0.00532	CbGpPWpGaD
Agomelatine—Diarrhoea—Docetaxel—skin cancer	0.000342	0.00147	CcSEcCtD
Agomelatine—Dizziness—Docetaxel—skin cancer	0.000331	0.00142	CcSEcCtD
Agomelatine—MTNR1A—GPCR downstream signaling—PTGER4—skin cancer	0.000327	0.00496	CbGpPWpGaD
Agomelatine—MTNR1B—GPCR downstream signaling—PTGER4—skin cancer	0.000327	0.00496	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling by GPCR—SHH—skin cancer	0.000322	0.00488	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling by GPCR—SHH—skin cancer	0.000322	0.00488	CbGpPWpGaD
Agomelatine—Vomiting—Docetaxel—skin cancer	0.000318	0.00136	CcSEcCtD
Agomelatine—HTR2C—GPCR ligand binding—PTCH2—skin cancer	0.000317	0.00481	CbGpPWpGaD
Agomelatine—Headache—Docetaxel—skin cancer	0.000314	0.00134	CcSEcCtD
Agomelatine—MTNR1A—Signaling by GPCR—SMO—skin cancer	0.000305	0.00462	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling by GPCR—SMO—skin cancer	0.000305	0.00462	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling by GPCR—PTCH1—skin cancer	0.000305	0.00462	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling by GPCR—PTCH1—skin cancer	0.000305	0.00462	CbGpPWpGaD
Agomelatine—HTR2C—Class A/1 (Rhodopsin-like receptors)—MC1R—skin cancer	0.000301	0.00456	CbGpPWpGaD
Agomelatine—Nausea—Docetaxel—skin cancer	0.000297	0.00127	CcSEcCtD
Agomelatine—MTNR1A—Signaling by GPCR—PTGER4—skin cancer	0.000297	0.0045	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling by GPCR—PTGER4—skin cancer	0.000297	0.0045	CbGpPWpGaD
Agomelatine—HTR2B—GPCRs, Class A Rhodopsin-like—PTGER4—skin cancer	0.000287	0.00434	CbGpPWpGaD
Agomelatine—HTR2B—GPCR ligand binding—MC1R—skin cancer	0.000284	0.00431	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—GLI2—skin cancer	0.00028	0.00424	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—GLI2—skin cancer	0.00028	0.00424	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—MC1R—skin cancer	0.000267	0.00404	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—MC1R—skin cancer	0.000267	0.00404	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—GLI1—skin cancer	0.000263	0.00399	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—GLI1—skin cancer	0.000263	0.00399	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—SUFU—skin cancer	0.000249	0.00378	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—SUFU—skin cancer	0.000249	0.00378	CbGpPWpGaD
Agomelatine—HTR2B—Class A/1 (Rhodopsin-like receptors)—PTGER4—skin cancer	0.000246	0.00372	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—RHOU—skin cancer	0.000244	0.0037	CbGpPWpGaD
Agomelatine—MTNR1A—Circadian rythm related genes—TP53—skin cancer	0.000243	0.00369	CbGpPWpGaD
Agomelatine—MTNR1B—Circadian rythm related genes—TP53—skin cancer	0.000243	0.00369	CbGpPWpGaD
Agomelatine—HTR2C—GPCRs, Class A Rhodopsin-like—PTGER4—skin cancer	0.000231	0.0035	CbGpPWpGaD
Agomelatine—HTR2C—GPCR ligand binding—MC1R—skin cancer	0.000229	0.00347	CbGpPWpGaD
Agomelatine—MTNR1A—Circadian rythm related genes—IL6—skin cancer	0.000223	0.00338	CbGpPWpGaD
Agomelatine—MTNR1B—Circadian rythm related genes—IL6—skin cancer	0.000223	0.00338	CbGpPWpGaD
Agomelatine—HTR2B—GPCR ligand binding—SHH—skin cancer	0.000203	0.00307	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—PTCH2—skin cancer	0.000202	0.00306	CbGpPWpGaD
Agomelatine—HTR2C—Class A/1 (Rhodopsin-like receptors)—PTGER4—skin cancer	0.000198	0.003	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—RHOU—skin cancer	0.000197	0.00298	CbGpPWpGaD
Agomelatine—HTR2B—GPCR ligand binding—PTCH1—skin cancer	0.000192	0.00291	CbGpPWpGaD
Agomelatine—HTR2B—GPCR ligand binding—SMO—skin cancer	0.000192	0.00291	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—SHH—skin cancer	0.00019	0.00288	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—SHH—skin cancer	0.00019	0.00288	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—RASA1—skin cancer	0.000189	0.00286	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—RASA1—skin cancer	0.000189	0.00286	CbGpPWpGaD
Agomelatine—HTR2B—GPCR ligand binding—PTGER4—skin cancer	0.000187	0.00283	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—PTCH1—skin cancer	0.00018	0.00273	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—SMO—skin cancer	0.00018	0.00273	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—SMO—skin cancer	0.00018	0.00273	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—PTCH1—skin cancer	0.00018	0.00273	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—PTGER4—skin cancer	0.000176	0.00266	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—PTGER4—skin cancer	0.000176	0.00266	CbGpPWpGaD
Agomelatine—CYP2C9—Arachidonic acid metabolism—PTGS2—skin cancer	0.000165	0.00251	CbGpPWpGaD
Agomelatine—HTR2C—GPCR ligand binding—SHH—skin cancer	0.000163	0.00248	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—PTCH2—skin cancer	0.000163	0.00247	CbGpPWpGaD
Agomelatine—HTR2B—GPCR downstream signaling—MC1R—skin cancer	0.000161	0.00243	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—FOXO4—skin cancer	0.000155	0.00235	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—FOXO4—skin cancer	0.000155	0.00235	CbGpPWpGaD
Agomelatine—HTR2C—GPCR ligand binding—SMO—skin cancer	0.000155	0.00235	CbGpPWpGaD
Agomelatine—HTR2C—GPCR ligand binding—PTCH1—skin cancer	0.000155	0.00235	CbGpPWpGaD
Agomelatine—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—skin cancer	0.000151	0.00229	CbGpPWpGaD
Agomelatine—HTR2C—GPCR ligand binding—PTGER4—skin cancer	0.000151	0.00228	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—MC1R—skin cancer	0.000146	0.00221	CbGpPWpGaD
Agomelatine—CYP1A2—Arachidonic acid metabolism—PTGS2—skin cancer	0.000141	0.00214	CbGpPWpGaD
Agomelatine—HTR2C—GPCR downstream signaling—MC1R—skin cancer	0.00013	0.00196	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	0.000124	0.00188	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—PTCH2—skin cancer	0.000119	0.00181	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—MC1R—skin cancer	0.000118	0.00178	CbGpPWpGaD
Agomelatine—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—skin cancer	0.000118	0.00178	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	0.000106	0.0016	CbGpPWpGaD
Agomelatine—HTR2B—GPCR downstream signaling—PTGER4—skin cancer	0.000106	0.0016	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—SHH—skin cancer	0.000104	0.00157	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—TERT—skin cancer	0.000104	0.00157	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—TERT—skin cancer	0.000104	0.00157	CbGpPWpGaD
Agomelatine—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—skin cancer	0.000101	0.00153	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—SMO—skin cancer	9.86e-05	0.00149	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—PTCH1—skin cancer	9.86e-05	0.00149	CbGpPWpGaD
Agomelatine—HTR2B—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—skin cancer	9.74e-05	0.00147	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—PTCH2—skin cancer	9.62e-05	0.00146	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—PTGER4—skin cancer	9.59e-05	0.00145	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—GLI2—skin cancer	9.03e-05	0.00137	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling by GPCR—NRAS—skin cancer	8.73e-05	0.00132	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling by GPCR—NRAS—skin cancer	8.73e-05	0.00132	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—MC1R—skin cancer	8.62e-05	0.00131	CbGpPWpGaD
Agomelatine—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—skin cancer	8.6e-05	0.0013	CbGpPWpGaD
Agomelatine—HTR2C—GPCR downstream signaling—PTGER4—skin cancer	8.52e-05	0.00129	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—GLI1—skin cancer	8.49e-05	0.00129	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—SHH—skin cancer	8.39e-05	0.00127	CbGpPWpGaD
Agomelatine—HTR2B—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—skin cancer	8.38e-05	0.00127	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—BRAF—skin cancer	8.2e-05	0.00124	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—BRAF—skin cancer	8.2e-05	0.00124	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—SUFU—skin cancer	8.05e-05	0.00122	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—PTCH1—skin cancer	7.95e-05	0.0012	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—SMO—skin cancer	7.95e-05	0.0012	CbGpPWpGaD
Agomelatine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—skin cancer	7.85e-05	0.00119	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—PTGER4—skin cancer	7.74e-05	0.00117	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling by GPCR—KRAS—skin cancer	7.51e-05	0.00114	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling by GPCR—KRAS—skin cancer	7.51e-05	0.00114	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—GLI2—skin cancer	7.29e-05	0.0011	CbGpPWpGaD
Agomelatine—HTR2B—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—skin cancer	7.12e-05	0.00108	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—MC1R—skin cancer	6.95e-05	0.00105	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—GLI1—skin cancer	6.85e-05	0.00104	CbGpPWpGaD
Agomelatine—HTR2B—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—skin cancer	6.82e-05	0.00103	CbGpPWpGaD
Agomelatine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—skin cancer	6.76e-05	0.00102	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—SUFU—skin cancer	6.5e-05	0.000984	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling by GPCR—HRAS—skin cancer	6.38e-05	0.000967	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling by GPCR—HRAS—skin cancer	6.38e-05	0.000967	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—SHH—skin cancer	6.14e-05	0.00093	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling by GPCR—IL6—skin cancer	6.11e-05	0.000926	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling by GPCR—IL6—skin cancer	6.11e-05	0.000926	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—RASA1—skin cancer	6.1e-05	0.000924	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—PTCH1—skin cancer	5.82e-05	0.000882	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—SMO—skin cancer	5.82e-05	0.000882	CbGpPWpGaD
Agomelatine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—skin cancer	5.75e-05	0.00087	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—PTGER4—skin cancer	5.67e-05	0.000858	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—PLIN2—skin cancer	5.52e-05	0.000836	CbGpPWpGaD
Agomelatine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—skin cancer	5.5e-05	0.000833	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—NRAS—skin cancer	5.16e-05	0.000781	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—NRAS—skin cancer	5.16e-05	0.000781	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—FOXO4—skin cancer	5.01e-05	0.000758	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—SHH—skin cancer	4.95e-05	0.00075	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—RASA1—skin cancer	4.92e-05	0.000746	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—PLIN2—skin cancer	4.72e-05	0.000714	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—SMO—skin cancer	4.7e-05	0.000711	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—PTCH1—skin cancer	4.7e-05	0.000711	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—PTGER4—skin cancer	4.57e-05	0.000693	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—CSPG4—skin cancer	4.45e-05	0.000674	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—KRAS—skin cancer	4.44e-05	0.000672	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—KRAS—skin cancer	4.44e-05	0.000672	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—FOXO4—skin cancer	4.04e-05	0.000612	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—TP53—skin cancer	3.94e-05	0.000597	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—TP53—skin cancer	3.94e-05	0.000597	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—CSPG4—skin cancer	3.8e-05	0.000576	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—HRAS—skin cancer	3.77e-05	0.000571	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—HRAS—skin cancer	3.77e-05	0.000571	CbGpPWpGaD
Agomelatine—MTNR1B—Signaling Pathways—IL6—skin cancer	3.61e-05	0.000547	CbGpPWpGaD
Agomelatine—MTNR1A—Signaling Pathways—IL6—skin cancer	3.61e-05	0.000547	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—TERT—skin cancer	3.34e-05	0.000506	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—ENO2—skin cancer	3.02e-05	0.000458	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—NRAS—skin cancer	2.82e-05	0.000427	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—TERT—skin cancer	2.7e-05	0.000409	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—BRAF—skin cancer	2.65e-05	0.000401	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—ENO2—skin cancer	2.58e-05	0.000391	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—KRAS—skin cancer	2.42e-05	0.000367	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	2.37e-05	0.000358	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—NRAS—skin cancer	2.27e-05	0.000344	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—BRAF—skin cancer	2.14e-05	0.000324	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—HRAS—skin cancer	2.06e-05	0.000312	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	2.02e-05	0.000306	CbGpPWpGaD
Agomelatine—HTR2B—Signaling by GPCR—IL6—skin cancer	1.97e-05	0.000299	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—KRAS—skin cancer	1.96e-05	0.000296	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—ERCC2—skin cancer	1.76e-05	0.000266	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—NRAS—skin cancer	1.66e-05	0.000252	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—HRAS—skin cancer	1.66e-05	0.000252	CbGpPWpGaD
Agomelatine—HTR2C—Signaling by GPCR—IL6—skin cancer	1.59e-05	0.000241	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—ERCC2—skin cancer	1.5e-05	0.000227	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—KRAS—skin cancer	1.43e-05	0.000217	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—NRAS—skin cancer	1.34e-05	0.000203	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—TP53—skin cancer	1.27e-05	0.000193	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—HRAS—skin cancer	1.22e-05	0.000184	CbGpPWpGaD
Agomelatine—HTR2B—Signaling Pathways—IL6—skin cancer	1.17e-05	0.000177	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—KRAS—skin cancer	1.16e-05	0.000175	CbGpPWpGaD
Agomelatine—CYP2C9—Metabolism—PTGS2—skin cancer	1.05e-05	0.00016	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—TP53—skin cancer	1.03e-05	0.000156	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—HRAS—skin cancer	9.82e-06	0.000149	CbGpPWpGaD
Agomelatine—HTR2C—Signaling Pathways—IL6—skin cancer	9.4e-06	0.000142	CbGpPWpGaD
Agomelatine—CYP1A2—Metabolism—PTGS2—skin cancer	9e-06	0.000136	CbGpPWpGaD
